Drug intelligence / Profile preview

MUMAB 7E9

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MUMAB 7E9 is a function-blocking monoclonal antibody that specifically targets human alpha-calcitonin gene-related peptide (CGRP). It works by inhibiting neurogenic vasodilation, which is a key process in migraine pathophysiology. The drug has been investigated as a potential preventive therapy for migraine.

Targets

CGRP (Calcitonin gene-related peptide)

Beyond the preview

Go deeper on MUMAB 7E9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUMAB 7E9.

Explore the full profile